期刊
TRENDS IN BIOTECHNOLOGY
卷 28, 期 7, 页码 355-362出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2010.03.007
关键词
-
资金
- Ministerio de Ciencia e Innovacion [BIO2008-03233, BIO2008-00205]
- Comunidad Autonoma de Madrid [BIO-0236-2006]
- European Union
Evolutionary pressure has selected antibodies as key immune molecules acting against foreign pathogens. The development of monoclonal antibody technology has allowed their widespread use in research, real-time diagnosis and treatment of multiple diseases, including cancer. However, compared with hematologic malignancies, solid tumors have often proven to be relatively resistant to antibody-based therapies. In an attempt to improve the tumor-targeting efficacy of antibodies, new formats with modified, multivalent properties have been generated. Initially, these formats imitated the structure of native IgG, creating mostly monospecific, bivalent antibodies. Recently, novel trivalent antibodies have been developed to maximize tumor targeting capabilities through enhanced biodistribution and functional affinity. We review recent advances in the engineering of multivalent antibodies and further discuss their promise as agents for in vivo diagnostics and therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据